Last reviewed · How we verify
VVN461 Ophthalmic Solution 0.25% — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
VVN461 Ophthalmic Solution 0.25% (VVN461 Ophthalmic Solution 0.25%) — VivaVision Biotech, Inc.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| VVN461 Ophthalmic Solution 0.25% TARGET | VVN461 Ophthalmic Solution 0.25% | VivaVision Biotech, Inc | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- VVN461 Ophthalmic Solution 0.25% CI watch — RSS
- VVN461 Ophthalmic Solution 0.25% CI watch — Atom
- VVN461 Ophthalmic Solution 0.25% CI watch — JSON
- VVN461 Ophthalmic Solution 0.25% alone — RSS
Cite this brief
Drug Landscape (2026). VVN461 Ophthalmic Solution 0.25% — Competitive Intelligence Brief. https://druglandscape.com/ci/vvn461-ophthalmic-solution-0-25. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab